These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Solheim BG Clin Med Res; 2006 Sep; 4(3):209-17. PubMed ID: 16988101 [TBL] [Abstract][Full Text] [Related]
6. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Klein HG; Glynn SA; Ness PM; Blajchman MA; Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769 [TBL] [Abstract][Full Text] [Related]
7. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Solheim BG; Granov DA; Juravlev VA; Krawczyk M; Kubishkin VA; Patutko UI; Raab R Vox Sang; 2005 Jul; 89(1):19-26. PubMed ID: 15938736 [TBL] [Abstract][Full Text] [Related]
8. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Shanwell A; Andersson TM; Rostgaard K; Edgren G; Hjalgrim H; Norda R; Melbye M; Nyrén O; Reilly M Vox Sang; 2009 May; 96(4):316-23. PubMed ID: 19254234 [TBL] [Abstract][Full Text] [Related]
9. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Sinnott P; Bodger S; Gupta A; Brophy M Eur J Immunogenet; 2004 Dec; 31(6):271-4. PubMed ID: 15548265 [TBL] [Abstract][Full Text] [Related]
10. Pathogen-reduction systems for blood components: the current position and future trends. Seghatchian J; de Sousa G Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168 [TBL] [Abstract][Full Text] [Related]
11. [Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate]. Spannagl M; Joch Ch; Heindl B Hamostaseologie; 2006 Aug; 26(3 Suppl 1):S36-40. PubMed ID: 16953291 [TBL] [Abstract][Full Text] [Related]
12. Risks and side effects of therapy with plasma and plasma fractions. MacLennan S; Barbara JA Best Pract Res Clin Haematol; 2006; 19(1):169-89. PubMed ID: 16377549 [TBL] [Abstract][Full Text] [Related]
13. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. AuBuchon JP; Birkmeyer JD JAMA; 1994 Oct; 272(15):1210-4. PubMed ID: 7933351 [TBL] [Abstract][Full Text] [Related]
14. Study on preparation of universal plasma in Chinese Han population. Wang S; Zhou W; Zhuang Y; Zhang D; Li H; Wang D Transfus Apher Sci; 2012 Oct; 47(2):167-70. PubMed ID: 22874436 [TBL] [Abstract][Full Text] [Related]
15. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Jilma-Stohlawetz P; Kursten FW; Walasek C; Horvath M; Leitner G; List J; Quehenberger P; Schwameis M; Bartko J; Jilma B Transfusion; 2011 Jun; 51(6):1228-40. PubMed ID: 21332722 [TBL] [Abstract][Full Text] [Related]
16. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902 [TBL] [Abstract][Full Text] [Related]
17. In search of plentiful universal donor plasma: what might Landsteiner say? Quillen K Transfusion; 2013 Aug; 53(8):1863-4. PubMed ID: 23927641 [No Abstract] [Full Text] [Related]